The mixture with Auden Mckenzie adds approximately 175 new generic and branded items, as well as a pipeline of approximately 40 additional products, in a variety of dosage forms, for treatments across a broad spectrum of therapeutic areas.. PRESS RELEASE DUBLIN,1 June, 2015/PRNewswire/ –Actavis plc today announced that it has finished its acquisition ofAuden Mckenzie Holdings Small, a dynamic and fast growing company centered on the development, marketing and licensing of specific niche market generic drugs and proprietary brands in the united kingdom. Actavisacquired Auden Mckenzie for approximately £306 million in cash, plus a two-year royalty on a %age of gross earnings of one of Auden Mckenzie's items.announced today that it intends to provide $450 million of senior notes due 2018 through a private placement, subject to market and other circumstances.0 million aggregate principal amount of 7.875 percent Senior Notes due 2016 , to settle outstanding revolving borrowings in the aggregate principal amount of around $97.5 million under its credit agreement and for working capital and other general corporate purposes, like the financing of potential acquisitions or investments, stock repurchases and capital expenditures.

Adaptimmune melanoma trial opening Today that it has opened a Phase We/II Adaptimmune announced, two cohort, open up label clinical trial in metastatic melanoma in Washington University, St.